Results 11 to 20 of about 39,319 (333)

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. [PDF]

Leukemia, 2019
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or ...
Bairey, Osnat, Barr, Paul M., Burger, Jan A., Coutre, Steven E., Dai, Sandra, Dean, James P., Devereux, Stephen, Ghia, P, Grosicki, Sebastian, Hillmen, Peter, Kipps, Thomas J., Lal, Indu, McCarthy, Helen, Moreno, Carol, Offner, Fritz, Owen, Carolyn, Robak, Tadeusz, Simpson, David, Tedeschi, Alessandra, Universitat Autònoma de Barcelona   +19 more
core   +4 more sources

RETRACTED ARTICLE: Ibrutinib facilitates the sensitivity of colorectal cancer cells to ferroptosis through BTK/NRF2 pathway

Cell Death and Disease, 2023
Ibrutinib is a drug that inhibits the protein Burton’s tyrosine kinase and thereby the nuclear translocation of Nrf2, which played a key role in mediating the activation of antioxidants during stress conditions and ferroptosis resistance.
Jin-Feng Zhu, Yi Liu, Wen-Ting Li, Ming-Hui Li, Chao-Hui Zhen, Pei-Wei Sun, Ji-Xin Chen, Wen-Hao Wu, Wei Zeng   +8 more
doaj   +2 more sources

Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells [PDF]

Brazilian Journal of Medical and Biological Research
Despite the widespread use of R-CHOP therapy in diffuse large B-cell lymphoma (DLBCL), the therapeutic efficacy for this disease remains suboptimal, primarily due to the heterogeneity of refractory and/or relapsed diseases.
Fengbo Jin, Limei He, Yingying Chen, Wanlu Tian, Lixia Liu, Ling Ge, Wei Qian, Leiming Xia, Mingzhen Yang   +8 more
doaj   +3 more sources

Ibrutinib [PDF]

Australian Prescriber, 2015

openalex   +3 more sources

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [PDF]

New England Journal of Medicine, 2013
BACKGROUND The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions. Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and
John C. Byrd, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Barbara Grant, Jeff P. Sharman, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Juthamas Sukbuntherng, Betty Chang, Fong Clow, Eric Hedrick, Joseph J. Buggy, Danelle F. James, Susan O’Brien   +20 more
openalex   +2 more sources

Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL [PDF]

New England Journal of Medicine, 2018
BACKGROUND Ibrutinib has been approved by the Food and Drug Administration for the treatment of patients with untreated chronic lymphocytic leukemia (CLL) since 2016 but has not been compared with chemoimmunotherapy.
Bartlett, Nancy L.
core   +3 more sources

Extrahepatic metabolism of ibrutinib [PDF]

Investigational New Drugs, 2020
SummaryIbrutinib is a first-in-class Bruton’s kinase inhibitor used in the treatment of multiple lymphomas. In addition to CYP3A4-mediated metabolism, glutathione conjugation can be observed. Subsequently, metabolism of the conjugates and finally their excretion in feces and urine occurs. These metabolites, however, can reach substantial concentrations
Rosalinde Masereeuw, Rolf W. Sparidans, Alfred H. Schinkel, Amer Jamalpoor, Roeland E Wasmann, Roeland E Wasmann, Manoe J. Janssen, Jos H. Beijnen, Jos H. Beijnen, Matthijs J. van Haren, Matthijs J. van Haren, Stephanie van Hoppe, Stephanie van Hoppe, Johannes J.M. Rood   +13 more
openaire   +5 more sources

Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.

New England Journal of Medicine, 2022
BACKGROUND In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic ...
Jennifer R. Brown, B. Eichhorst, P. Hillmen, W. Jurczak, M. Kaźmierczak, N. Lamanna, S. O'brien, C. Tam, L. Qiu, K. Zhou, M. Šimkovič, J. Mayer, A. Gillespie-Twardy, A. Ferrajoli, P. Ganly, R. Weinkove, S. Grosicki, A. Mital, T. Robak, A. Osterborg, H. Yimer, T. Salmi, M. Wang, L. Fu, Jessica Li, Kenneth Wu, A. Cohen, M. Shadman   +27 more
semanticscholar   +1 more source

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

Journal of Clinical Oncology, 2023
The phase III ASPEN study demonstrated the comparable efficacy and improved safety of zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia (WM). Here, we report long-term follow-up outcomes from ASPEN.
M. Dimopoulos, Stephen Samuel Opat, S. D’Sa, W. Jurczak, Hui-Peng Lee, G. Cull, R. Owen, P. Marlton, B. Wahlin, R. García-Sanz, H. McCarthy, S. Mulligan, A. Tedeschi, J. Castillo, J. Czyż, C. Fernández de Larrea, D. Belada, E. Libby, J. Matous, M. Motta, T. Siddiqi, M. Tani, M. Trněný, M. Minnema, C. Buske, V. Leblond, S. Treon, J. Trotman, W. Chan, J. Schneider, H. Allewelt, S. Patel, A. Cohen, C. Tam   +33 more
semanticscholar   +1 more source

Arrhythmia Patterns in Patients on Ibrutinib [PDF]

Frontiers in Cardiovascular Medicine, 2022
Introduction: Ibrutinib, a Bruton's tyrosine kinase inhibitor (TKI) used primarily in the treatment of hematologic malignancies, has been associated with increased incidence of atrial fibrillation (AF), with limited data on its association with other tachyarrhythmias.
Muhammad Fazal, Ridhima Kapoor, Paul Cheng, Albert J. Rogers, Sanjiv M. Narayan, Paul Wang, Ronald M. Witteles, Alexander C. Perino, Tina Baykaner, June-Wha Rhee   +9 more
openaire   +3 more sources